At another locus—11q13.5—experimental evidence has emerged, supporting the candidate role of the top two prioritized genes—LRRC32 (encoding the GARP receptor) and EMSY. Rare missense mutations found in LRRC32 in patients with eczema decrease GARP expression on the activated T-regulatory cell surface and reduce the conversion of naive T cells into T-regulatory cells (Manz et al., 2016). This evidence concerns the gene LRRC32 and Eczematoid dermatitis.